{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.5","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"97.5","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"97.5","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"52.2","value":"0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"30.8","value":"0"},{"groupId":"OG005","lowerLimit":"0.2","upperLimit":"33.9","value":"7.1"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"60.2","value":"0"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"60.2","value":"0"},{"groupId":"OG008","lowerLimit":"0.0","upperLimit":"84.2","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"2"}],"units":"Participants"}],"description":"Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR). Complete response was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10 mm). All target lesions must be assessed. Partial response was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.","dispersionType":"95% Confidence Interval","groups":[{"description":"PF-06952229 was administered at a dose of 20 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG000","title":"Part 1A: PF-06952229 20mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 40 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG001","title":"Part 1A: PF-06952229 40mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 80 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG002","title":"Part 1A: PF-06952229 80mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 150 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG003","title":"Part 1A: PF-06952229 150mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 250 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG004","title":"Part 1A: PF-06952229 250mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 375 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG005","title":"Part 1A: PF-06952229 375mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 500 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG006","title":"Part 1A: PF-06952229 500mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 250 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally once a day (QD) as continuous daily dosing.","id":"OG007","title":"Part 1B: PF-06952229 250mg + Enzalutamide"},{"description":"PF-06952229 was administered at a dose of 375 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally QD as continuous daily dosing.","id":"OG008","title":"Part 1B: PF-06952229 375mg + Enzalutamide"}],"paramType":"NUMBER","populationDescription":"Population included all enrolled participants who received at least 1 dose of investigational product, had baseline assessment and at least 1 post baseline assessment, disease progression, or death before the first tumor assessment.","reportingStatus":"POSTED","timeFrame":"Baseline and every 8 to 12 weeks through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.","title":"Percentage of Participants With Objective Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}